Dianthus Therapeutics Banner

Investors & Media

Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)

Our Mission

To Harness the Power of Selectivity in Complement Therapeutics

We envision the full potential of complement therapeutics lies within the power of selectivity. Our lead antibody, DNTH103, is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein that drives disease pathology – enabling less frequent and more convenient self-administered subcutaneous injections to improve the lives of patients.

Science flower image


More events are coming soon.